Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 1/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | PI4KA | P42356 | 2/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | GAPDH | P04406 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | STAT6 | P42226 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982189 | 1.00 | ADA (0.62) | ADAADORA3POLBADORA2AADORA2B | |
| SCHEMBL29763162 | 1.00 | ADA (0.62) | ADAADORA3POLBADORA2AADORA2B | |
| SCHEMBL14565317 | 1.00 | ADA (0.62) | ADAADORA3POLBADORA2AADORA2B | |
| SCHEMBL20434921 | 1.00 | ADA (0.62) | ADAADORA3POLBADORA2AADORA2B | |
| SCHEMBL4127888 | 1.00 | ADA (0.62) | ADAADORA3POLBADORA2AADORA2B | |
| SCHEMBL25496381 | 0.88 | AHCY (0.53) | ADAADORA3POLBADORA2AADORA2B | |
| Deoxyadenosine SCHEMBL19877 | 0.88 | HIF1A (0.71) | ADAADORA3POLBADORA2AADORA2B | |
| Deoxyadenosine SCHEMBL5182039 | 0.88 | HIF1A (0.71) | ADAADORA3POLBADORA2AADORA2B | |
| Deoxyadenosine SCHEMBL193181 | 0.88 | HIF1A (0.71) | ADAADORA3POLBADORA2AADORA2B | |
| Deoxyadenosine SCHEMBL21637036 | 0.88 | HIF1A (0.71) | ADAADORA3POLBADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428658-B2 | Methods and compositions for enzymatic polymerization of N3′→P5′ phosphoramidate DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2025-09-30 | — | — | US | claimed |
| US-20240309418-A1 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | MASSACHUSETTS GEN HOSPITAL (US) | 2024-09-19 | — | — | US | claimed |
| US-20230026693-A1 | Methods and Compositions for Enzymatic Polymerization of N3` -> P5` Phosphoramidate DNA | THE GENERAL HOSPITAL CORPORATION | 2023-01-26 | — | — | US | claimed |
| US-10184142-B2 | Biocatalytic production of nucleoside analogues as active pharmaceutical ingredients | PLASMIA BIOTECH, S.L. (ES) | 2019-01-22 | — | — | US | claimed |
| WO-2017164615-A1 | METHOD FOR PREPARING 3'-AMINO-2',3'-DIDEOXYADENOSINE BY USING NUCLEOSIDE PHOSPHORYLASE DERIVED FROM BACILLUS | ST PHARM CO., LTD. (KR) | 2017-09-28 | — | — | WO | claimed |
| EP-2742153-A1 | PROTEIN AND PEPTIDE LIBRARIES | The General Hospital Corporation (US) | 2014-06-18 | — | — | EP | claimed |
| WO-2013019794-A1 | PROTEIN AND PEPTIDE LIBRARIES | THE GENERAL HOSPITAL CORPORATION (US) | 2013-02-07 | — | — | WO | claimed |
| US-12428658-B2 | Methods and compositions for enzymatic polymerization of N3′→P5′ phosphoramidate DNA | THE GENERAL HOSPITAL CORPORATION (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240309418-A1 | ENZYMATIC METHODS AND COMPOSITIONS FOR POLYMERIZATION OF PHOSPHORAMIDATE AND THIOPHOSPHORAMIDATE-LINKED DNA | MASSACHUSETTS GEN HOSPITAL (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240300992-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2024-09-12 | — | — | US | disclosed |
| US-20240034748-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | GERON CORP (US) | 2024-02-01 | — | — | US | disclosed |
| EP-3137479-B1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF MAKING THE SAME | GERON CORP (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11739114-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2013019794-A1 | PROTEIN AND PEPTIDE LIBRARIES | THE GENERAL HOSPITAL CORPORATION (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20090105468-A1 | Synthesis of Protected 3'-Amino Nucleoside Monomers | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2009-04-23 | — | — | US | disclosed |
| US-7485717-B2 | Synthesis of protected 3′-amino nucleoside monomers | GERON CORPORATION (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1778711-A1 | SYNTHESIS OF PROTECTED 3'-AMINO NUCLEOSIDE MONOMERS | Geron Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | METKINEN OY (FI) | 2007-03-22 | — | — | US | disclosed |
| WO-2006014387-A1 | SYNTHESIS OF PROTECTED 3’-AMINO NUCLEOSIDE MONOMERS | GERON CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060009636-A1 | Synthesis of protected 3'-amino nucleoside monomers | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739114-B2 | Oligonucleotide compositions and methods of making the same | RNGTT, NSUN2, POLN | ADA 240/4885ADORA3 491/4885POLB 10/4885 |
| US-20240034748-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | NT5C3B, RNMT, UMPS | ADA 18/4885ADORA3 236/4885POLB 158/4885 |
| US-20070065922-A1 | Biocatalytic synthesis of aminodeoxy purine N9-beta-D-nucleosides containing 3-amino-3-deoxy-beta-D-ribofuranose, 3-amino-2,3-dideoxy-beta-D-ribofuranose, and 2-amino-2-deoxy-beta-D-ribofuranose as sugar moieties | DUT, UNG, GALE | ADA 11/4885ADORA3 265/4885POLB 696/4885 |
| US-20240300992-A1 | Synthesis of Protected 3'-amino Nucleoside Monomers | NT5C3B, RNMT, UMPS | ADA 18/4885ADORA3 236/4885POLB 158/4885 |
| US-20060009636-A1 | Synthesis of protected 3'-amino nucleoside monomers | NT5C3B, RNMT, UMPS | ADA 18/4885ADORA3 236/4885POLB 158/4885 |
| US-20090105468-A1 | Synthesis of Protected 3'-Amino Nucleoside Monomers | NT5C3B, RNMT, UMPS | ADA 18/4885ADORA3 236/4885POLB 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.